Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553–60.
Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038–40.
Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood. 2016;127:2847–55.
Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015;373:1733–47.
Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733–40.
Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000;96:2981–6.
Caeser R, Collord G, Yao WQ, Chen Z, Vassiliou GS, Beer PA, et al. Targeting MEK in vemurafenib-resistant hairy cell leukemia. Leukemia. 2019;33:541–5.
Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013;10:390–9.
Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14:455–67.
Guedj M, Queant A, Funck-Brentano E, Kramkimel N, Lellouch J, Monnet D, et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA Ophthalmol. 2014;132:1421–5.
Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494:251–5.
Dooley AJ, Gupta A, Bhattacharyya M, Middleton MR. Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol. 2014;6:262–6.
Bohn JP, Pircher A, Wanner D, Vill D, Foeger B, Wolf D, et al. Low-dose vemurafenib in hairy cell leukemia patients with active infection. Am J Hematol. 2019;94:E180–2.
Tiacci E, De Carolis L, Simonetti E, Zaja F, Capponi M, Ambrosetti A, et al. The BRAF inhibitor vemurafenib plus rituximab produces a high rate of deep and durable responses in relapsed/refractory hairy cell leukemia: updated results of a phase-2 trial. Hematological Oncol. 2019;37:066
We thank Michael Perker (Hämatologisch-onkologische Schwerpunktpraxis, Weilheim, Germany), Thomas Mandel (Klink für Innere Medizin III, SLK-Kliniken Heilbronn, Klinikum am Plattenwald, Bad Friedrichshall, Germany), and Michael Steurer (Department of Internal Medicine V, Division of Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria) for collecting data. NL was supported by a HRCMM (Heidelberg Research Center for Molecular Medicine) short-term Career Development Fellowship. TR was supported by a physician scientist fellowship of the Medical Faculty of the University Heidelberg. SD was supported by a grant of the Heidelberg Research Centre for Molecular Medicine (HRCMM) and the BMBF junior group grant by the BMBF within the e:Med initiative. SD and TZ are supported by the Hairy Cell Leukemia Foundation.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liebers, N., Roider, T., Bohn, JP. et al. BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. Leukemia 34, 1454–1457 (2020). https://doi.org/10.1038/s41375-019-0646-y